Search results
Results from the WOW.Com Content Network
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
In mid-October 2018, Novartis announced it would acquire Endocyte Inc for $2.1 billion ($24 per share) merging it with a newly created subsidiary. [ 9 ] [ 10 ] Endocyte will bolster Novartis' offering in its radiopharmaceuticals business, with Endocyte's first in class candidate 177 Lu-PSMA-617 being targeted against metastatic castration ...
Novartis AG is a publicly traded Swiss holding company that operates through the Novartis Group and owns, directly or indirectly, all companies worldwide that operate as subsidiaries of the Novartis Group. [110] Novartis's businesses are divided into two operating divisions: Innovative Medicines and Sandoz (generics). [111]
Novartis, which is working on two other drug candidates to treat IgAN, added it plans to review the interim results with the U.S. Food and Drug Administration with a view to seeking accelerated ...
Ianalumab (INN; [1] development code VAY736) is a monoclonal antibody that is being investigated for autoimmune hepatitis, multiple sclerosis, pemphigus vulgaris, rheumatoid arthritis, Sjögren syndrome, and systemic lupus erythematosus.
For premium support please call: 800-290-4726 more ways to reach us
Novartis has also stated that the NITD will seek to make treatments developed by the NITD available without profit to the poor in developing nations in which these diseases are endemic. [3] In 2017, NITD moved out of Singapore to be beside Novartis' infectious diseases research headquarters in Emeryville, California, United States. [4]
Advanced Accelerator Applications (AAA or Adacap) is a France-based pharmaceutical group, specialized in the field of nuclear medicine. [1] The group operates in all three segments of nuclear medicine (PET, SPECT and therapy) to diagnose and treat serious conditions in the fields of oncology, neurology, cardiology, infectious and inflammatory diseases.